
Conference Coverage
Latest News

Translation: A Pharmacist’s Greatest Skill

What the Peptide Vote Actually Changes at My Counter (Hint: Not Much, Yet)

GLP-1s May Curb Lung Fibrosis in Diabetes, Long COVID

Ensitrelvir Approved for Postexposure Prophylaxis of COVID-19

What Does the FDA Advisory Committee’s Vote on 7 Peptides Mean for Pharmacy Practice?

Shorts










Podcasts
Videos
Continuing Education
All News

Erica Marini, PharmD, and Millad Sobhanian, PharmD, BCPS, unpack Auvelity's approval, efficacy data, and safety profile for treating agitation in Alzheimer disease.

Food as Medicine programs that do not include pharmacist-led food-drug interaction screening are clinically incomplete.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free on-body delivery system with potential workflow, patient-experience, and mechanistic advantages.

Taking a new medication is a step toward healing, but danger may lie in how different drugs, supplements, and even foods and drinks react behind the scenes.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naïve and BTK inhibitor–treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Most websites selling GLP-1 receptor agonists prescribed medication with minimal clinical vetting, raising safety concerns pharmacists should be aware of.

Pharmacists can use motivational interviewing as a technique to encourage influenza vaccination.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

Pharmacists can provide updated vaccine recommendations and offer immunizations during MTM consults.

The review combines mechanistic and real-world evidence to guide health care professionals through different scenarios in the MS treatment space.

Brendon Neuen, PhD, MBBS, discusses findings from the FIND-CKD study showing that finerenone benefits patients with nondiabetic chronic kidney disease (CKD) and glomerular disease, as well as those receiving combination SGLT2i therapy.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.

The FDA approved Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium, for up to 12 hours of relief from minor aches and pains in patients 12 years and older.

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

A yearlong trial suggests the tuberculosis vaccine may retrain immune cells in the brain and shift Alzheimer-related biomarkers in older adults without existing pathology.

Federal guidelines and clinical evidence suggest that doubling or even tripling up on shots is not only safe but is also a best practice.

Five consistent habits—not stock-picking or complex strategies—separate pharmacists who quietly build multi-million-dollar net worths from those who don't.

The autoinjector provides an accessible, at-home option for patients with chronic kidney disease or heart failure who need treatment for fluid buildup.

Although weight loss is a primary goal, the ultimate utility of these agents lies in their ability to reduce long-term morbidity.

Flu vaccine rates are lagging as hesitancy rises, but community pharmacists boost vaccination with trusted counseling, easy access, and outreach.

Plozasiran Slashes Triglycerides, Pancreatitis Events in sHTG
SHASTA-3 and SHASTA-4 also showed a statistically significant drop in acute pancreatitis events, supporting a planned US sNDA this year.

The first 2 weeks have produced a specific, recurring set of counter-level problems that have nothing to do with clinical appropriateness.

Cassandra Perkey, PharmD, BCOP, explains the operational, staffing, infrastructure, safety, and pharmacist-led requirements for successfully delivering CAR T-cell therapy in a community oncology setting.





























